Beyond Thalidomide: The Patient as an Agent of Change
Beyond Thalidomide aims to document the historical rise of patient engagement in drug-related disabilities, reshaping reproductive health discourse through global case studies and digital storytelling.
Projectdetails
Introduction
Beyond Thalidomide will trace the historical rise of patient engagement with drug-related disability through the second half of the twentieth century to understand how a novel empowered group transformed conceptions of (reproductive) health and disease in science and society.
Patient Engagement Mapping
The project will map the conditions in which patients became engaged with antenatal drug use and reconstruct how their actions have created political and scientific urgency since 1960. This multifaceted engagement resulted in clashes of expertise that connected actors in the ‘Global South’ and ‘North’, from Latin American countries through Central Africa, India, and Europe.
Challenges in Reproductive Health
The enforcement and stabilization of the development of approaches in reproductive health will be examined in light of the democratic and civil societal challenges they pose, beyond traditional accounts of expert-led, iatrogenic risk management.
Fields of Patient Engagement
BT will address these aims through analysis of four interlinked fields of patient engagement:
- Monitoring, and the surveillance of exogenous factors for birth defects
- Prevention, and the management of risks of antenatal drug use in health care systems
- Marketing, and the making of pharmaceutical products
- Legal Action, and court intervention
Digital Collection and Global History
Mapping these fields of action, BT will create an ambitious digital collection of patient life stories and a comprehensive integrated record of how patients engage.
Ground-breaking Approach
BT will, for the first time, deliver a global history of drug-related disability ‘from below’, which examines the shifting contours of ‘patients’ as actors. This project takes a ground-breaking approach to the historiography of reproductive health, combining high-impact global case studies with innovative research tools to explore the political, ethical, and social challenges of this alternative perspective.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.743 |
Totale projectbegroting | € 1.499.743 |
Tijdlijn
Startdatum | 1-1-2025 |
Einddatum | 31-12-2029 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSITAT WIENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Acting Out Disease. How Patient Organizations Shaped Modern MedicineThis project analyzes the historical impact of 20th-century patient organizations on modern medicine, exploring their role in shaping disease concepts and patient involvement in healthcare. | ERC Starting... | € 1.499.773 | 2023 | Details |
A Novel Approach to New Family-Forms, Assisted Reproductive Technologies and Transnationalism. A multi-sited ethnography: Spain, Denmark, Canada and IsraelThis project aims to explore the impact of assisted reproductive technologies on new family forms and transnationalism across Europe, North America, and the Middle East through multi-sited ethnography. | ERC Advanced... | € 2.039.969 | 2024 | Details |
Genetically anchored drug target discovery for neglected diseasesGenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases. | ERC Starting... | € 1.498.089 | 2024 | Details |
Health Simulations: Ethical and Societal Challenges of Digital TwinsSIMTWIN aims to analyze the ethical and societal implications of Digital Twins in healthcare to develop a robust governance framework for their use in health simulations. | ERC Starting... | € 1.497.275 | 2023 | Details |
Investigate maternal and paternal risk factors for violence during pregnancy: lasting impact for everyoneIMPROVE_LIFE aims to assess the risk factors and impacts of intimate partner violence during pregnancy, using biomarkers and cohort data to inform global prevention and policy strategies. | ERC Consolid... | € 1.999.924 | 2024 | Details |
Acting Out Disease. How Patient Organizations Shaped Modern Medicine
This project analyzes the historical impact of 20th-century patient organizations on modern medicine, exploring their role in shaping disease concepts and patient involvement in healthcare.
A Novel Approach to New Family-Forms, Assisted Reproductive Technologies and Transnationalism. A multi-sited ethnography: Spain, Denmark, Canada and Israel
This project aims to explore the impact of assisted reproductive technologies on new family forms and transnationalism across Europe, North America, and the Middle East through multi-sited ethnography.
Genetically anchored drug target discovery for neglected diseases
GenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases.
Health Simulations: Ethical and Societal Challenges of Digital Twins
SIMTWIN aims to analyze the ethical and societal implications of Digital Twins in healthcare to develop a robust governance framework for their use in health simulations.
Investigate maternal and paternal risk factors for violence during pregnancy: lasting impact for everyone
IMPROVE_LIFE aims to assess the risk factors and impacts of intimate partner violence during pregnancy, using biomarkers and cohort data to inform global prevention and policy strategies.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Personalised Adaptive MedicineThe PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence. | EIC Pathfinder | € 1.726.876 | 2024 | Details |
Personalised Adaptive Medicine
The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.